论文部分内容阅读
目的观察阿奇霉素对急性冠脉综合征(ACS)患者血清超敏C-反应蛋白(hs-CRP)的影响。方法ACS患者随机分为A、B组,A组行ACS常规治疗并用阿奇霉素(38例),B组只用ACS常规治疗(38例)。设C组为健康对照组(n=37)。治疗前、治疗后第4天及第8天抽血用免疫比浊法测定血清hs-CRP(分别用hs-CRP0、hs-CRP4、hs-CRP8表示)。结果A、B组hs-CRP0均明显高于C组(P=0.000,0.000)。A、B两组hs-CRP8与hs-CRP0和hs-CRP4比较均有统计学差异(A组:P=0.030,0.013;B组:P=0.044,0.006)。A和B两组间hs-CRP4、hs-CRP8差异无统计学意义(P=0.466,0.804)。结论对ACS患者行阿奇霉素治疗不能进一步降低hs-CRP。
Objective To investigate the effect of azithromycin on serum hs-CRP in patients with acute coronary syndrome (ACS). Methods ACS patients were randomly divided into group A and group B. Patients in group A underwent routine thrombolysis with azithromycin (38 cases) and group B (n = 38). Set C as a healthy control group (n = 37). Serum hs-CRP (hs-CRP0, hs-CRP4, hs-CRP8, respectively) was measured before treatment, on the 4th and 8th day after treatment. Results The hs-CRP0 of group A and B were significantly higher than that of group C (P = 0.000, 0.000). There was significant difference between hs-CRP8 and hs-CRP0 and hs-CRP4 in group A and B (group A: P = 0.030,0.013; group B: P = 0.044,0.006). There was no significant difference in hs-CRP4 and hs-CRP8 between A and B groups (P = 0.466,0.804). Conclusion Azithromycin treatment of patients with ACS can not further reduce hs-CRP.